These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2523144)

  • 61. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action.
    Hall BM; Pearce NW; Gurley KE; Dorsch SE
    J Exp Med; 1990 Jan; 171(1):141-57. PubMed ID: 2136906
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immune responses to organ allografts. III. Marked decrease in medullary thymocytes and splenic T lymphocytes after cyclosporin A treatment.
    Baldwin WM; Hutchinson IF; Meijer CJ; Tilney NL
    Transplantation; 1981 Feb; 31(2):117-20. PubMed ID: 7020171
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophage-colony stimulating factor prolong donor-specific rat cardiac allograft survival.
    DePaz HA; Oluwole OO; Adeyeri AO; Witkowski P; Jin MX; Hardy MA; Oluwole SF
    Transplantation; 2003 Feb; 75(4):521-8. PubMed ID: 12605121
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Endothelial target cell-dependent, differing patterns of chronic vascular renal allograft rejection in the rat.
    van Breda Vriesman JC; Vlek LF; Duistermaat E; Duijvestijn AM
    Transplant Proc; 1990 Dec; 22(6):2519-21. PubMed ID: 2264132
    [No Abstract]   [Full Text] [Related]  

  • 65. Prolongation of cardiac allograft survival with transforming growth factor-beta 1 in rats.
    Raju GP; Belland SE; Eisen HJ
    Transplantation; 1994 Aug; 58(3):392-6. PubMed ID: 8053069
    [No Abstract]   [Full Text] [Related]  

  • 66. Interleukin 2 receptor in rat allograft rejection.
    Bouchot O; Anegon I; Romaniuk A; Jacques Y; Soulillou JP
    Transplant Proc; 1990 Aug; 22(4):1995-7. PubMed ID: 2202134
    [No Abstract]   [Full Text] [Related]  

  • 67. The role of hyperimmune alloantiserum in allograft survival.
    Oluwasanmi JO
    Immunology; 1973 Nov; 25(5):881-9. PubMed ID: 4586741
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats.
    Stepkowski SM; Chen H; Daloze P; Kahan BD
    Transplant Proc; 1991 Feb; 23(1 Pt 1):507-8. PubMed ID: 1990602
    [No Abstract]   [Full Text] [Related]  

  • 69. Impact of a combined regimen of cyclosporine and 3M KCl extracted histocompatibility antigen on heterotopic rat cardiac allograft survival.
    Didlake RH; Kim EK; Kahan BD
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):1034-7. PubMed ID: 2968693
    [No Abstract]   [Full Text] [Related]  

  • 70. Prolongation of hepatic allograft survival in rat recipients treated with anti-lymphotoxin antibody.
    Teramoto K; Baquerizo A; Imagawa DK; Seu P; Hart J; Dempsey RA; Terasaki PI; Kamada N; Busuttil RW
    Transplant Proc; 1991 Feb; 23(1 Pt 1):602-3. PubMed ID: 1990621
    [No Abstract]   [Full Text] [Related]  

  • 71. Prolongation of rat hepatic allografts by pretreatment with donor splenocytes combined with peritransplant cyclosporine.
    Sun J; Wu M
    Transplant Proc; 1990 Aug; 22(4):1960-1. PubMed ID: 2117822
    [No Abstract]   [Full Text] [Related]  

  • 72. The effect of histocompatibility matching and cyclosporine on rat pancreas transplants.
    Bartlett ST; Dugoni WE
    Transplant Proc; 1990 Apr; 22(2):741-2. PubMed ID: 2327027
    [No Abstract]   [Full Text] [Related]  

  • 73. Elimination of OX8+ cells prolongs cardiac but not pancreatic allograft survival across minor (non-MHC) histocompatibility barriers.
    Roza AM; Johnson CP; Adams MB; Naji A
    Transplant Proc; 1990 Apr; 22(2):747-8. PubMed ID: 2327028
    [No Abstract]   [Full Text] [Related]  

  • 74. Graft enhancement and antiidiotypic antibody. Lymphocytes from long-term rat renal allograft recipients have normal responsiveness in vitro.
    Fitch FW; Weiss A; McKearn TJ; Stuart FP
    Transplant Proc; 1978 Jun; 10(2):367-72. PubMed ID: 79259
    [No Abstract]   [Full Text] [Related]  

  • 75. Immunogenicity of allograft components. I. Assay for immunogenicity.
    Soots A; Parthenais E; Nemlander A; Häyry P
    Cell Immunol; 1981 Jan; 57(1):85-91. PubMed ID: 7011575
    [No Abstract]   [Full Text] [Related]  

  • 76. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor.
    Foegh ML; Khirabadi BS; Rowles JR; Braquet P; Ramwell PW
    Transplantation; 1986 Jul; 42(1):86-8. PubMed ID: 3523888
    [No Abstract]   [Full Text] [Related]  

  • 77. Prolongation of rat cardiac allograft survival by a new immunosuppressant: chicken anti-rat lymphocyte globulin.
    Morris RE; Souther SG; Dong E; Vistnes LM; Shumway NE
    Surgery; 1974 Jul; 76(1):150-9. PubMed ID: 4601599
    [No Abstract]   [Full Text] [Related]  

  • 78. Prolongation of mouse skin allograft survival by cloned veto suppressor cells.
    Takahashi T; Maki T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):192-3. PubMed ID: 1824972
    [No Abstract]   [Full Text] [Related]  

  • 79. In vitro correlates of rejection. III. Immunologic models for the study of a variety of kidney and heart transplant rejection and prolongation phenomena.
    Guttmann RD
    Transplant Proc; 1978 Jun; 10(2):361-6. PubMed ID: 79258
    [No Abstract]   [Full Text] [Related]  

  • 80. Intragraft immune events causing vascularized organ graft rejection.
    Strom TB; Carpenter CB; Tilney NL; Suthanthiran M; Catto GR; Lundin AP; Milford EL
    Transplant Proc; 1978 Jun; 10(2):389-94. PubMed ID: 354128
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.